Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Wojciech Wojakowski,
Dr. Grzegorz Smolka,
In order to expand the clinical use of the LAA occlusion devices (WATCHMAN and Amplatzer Plug) the physician training programs need to be established to reduce the risk of procedural adverse events. The role of the percutaneous LAA closure also has to be re-evaluated in the era of new medications, such as dabigatran and rivaroxaban. Lastly the approach to patients with incomplete LAA sealing after device deployment with regard to long-term use of anticoagulants needs to be established.
The left atrial appendage (LAA) is a tubular muscular structure in continuity with the left atrium (LA). LAA resembles a crescent and is located anteriorly to the left superior pulmonary vein ,in the proximity of the free wall of the left ventricle. LAA communicates with the LA through the orifice located between the left superior pulmonary vein and left ventricular wall. During embryogenesis LAA develops from primordial left atrium during the third week of gestation. There is a considerable inter-individual variability in the shape and size of LAA. In approximately 55% of cases LAA has two lobes. Pathology series showed that mean volume of LAA is approximately 5.2 ml and the mean orifice diameters 15-27 mm. Functions of the LAA include modulation of the sympathetic and parasympathetic tone, decompression of the left atrium in the setting of elevated atrial pressure, production of natriuretic peptides (ANP, BNP) and contributes to the diastolic filling of the left ventricle. Interestingly LAA displays a unique quadriphasic pattern of contraction [1-3].
Microscopic and macroscopic anatomy of the LAA changes significantly in chronic atrial fibrillation (AF) with smoothening of the internal surface as well as fibrosis and thickening of the endocardium. In addition, the volume of the LAA increases in AF. LAA plays a major role in the pathology associated with AF, because it is a most common place of thrombus formation. Formation of thrombus and its release from LAA leads to embolic stroke. High risk of thrombus formation is a result of the low-flow hemodynamics in the LAA. It is estimated that as much as 90% of strokes in patients with AF not associated with valvular heart disease, can be attributed to formation of thrombi in the LAA. Thrombi are also located in LAA in 50% of cases of AP coexisting with valvular heart disease. Reduced contractility of the LAA may occasionally lead to thrombus formation even in patients with sinus rhythm [3-6].
The benefits of oral anticoagulation in chronic AF are proven with regards to prevention of embolic stroke in a multitude of studies (AFASAK, BAATAF, CAFA, SPAF, SPINAF). The clinical efficiency of oral anticoagulants is however limited due to substantial rate of side effects, including a high risk of bleeding and important interactions with food and other medications. Moreover the need for frequent laboratory testing to check the efficiency of anticoagulation by measuring international normalized ratio (INR) and the need to dose titration lead to poor compliance. Several studies have shown that only 40-55% of patients with AF receive warfarin. The use of oral anticoagulants was particularly low in the elderly despite a high risk of stroke. In addition, many patients with AF present with contraindications for life-long use of oral anticoagulants. Given the important role played by LAA in the pathogenesis of embolic stroke, early attempts to reduce the risk by surgical removal or more recently ligation during the cardiac surgery were made. This approach is limited however by the need for major surgical procedure and a high rate of incomplete occlusion of the LAA orifice which might contribute to a high residual risk of stroke. Data on surgical LAA closure showed that such procedure is feasible and safe [3, 7-9]. Because of thisa less invasive approach of percutaneous LAA closure was translated from animal models into the clinical setting and a growing body of evidence has shown its safety and feasibility.
Echocardiography. Transthoracic echocardiography (TTE) is not sensitive enough to detect the presence of thrombi and to assess the anatomy and dimensions of the LAA. Recently, the 3-dimensional TTE is recognised as a promising tool for the detection of LAA thrombi. Current gold-standard for the assessment of the LAA is transesophageal echocardiography which plays a crucial role during the procedure of percutaneous closure. Evaluation of the LAA by multiplane TEE is imperative due to the its anatomical complexity. The exact size of the LAA orifice has to be measured in several planes because of its often irregular shape. Computed tomography. Multi-slice CT (MSCT) is more sensitive for the detection of LA thrombi than TTE and CT angiography yield high quality 3-D images of the LAA anatomy. Probably the sensitivity of MSCT for detection of LAA thrombi is comparable with TEE. Cardiac magnetic resonance imaging (cMRI) can be used for the imaging of LAA anatomy and when the contrast is used it can detect the thrombi, however the role of cMRI in percutaneous closure of the LAA needs to be established [10-12].
Three dedicated devices for LAA closure were tested in clinics: PLAATO, WATCHMAN and Amplatzer cardiac plug.
From the practical point of view, the most important difference between the last two devices is the regimen of antiplatelet and anticoagulant therapy used after the implantation.
Implantation is carried out without general anesthesia in the majority of cases under conscious sedation. Antibiotic is administered prior to the procedure as prophylaxis. Vascular access through femoral vein is obtained and the delivery system is introduced by superior transseptal puncture using standard transseptal needle and sheath. After the puncture, the bolus of unfractionated heparin is given to achieve clotting time ACT > 200 seconds. TEE or rarely ICE is used to guide the transseptal puncture. TEE or ICE is used to measure the dimensions of the LAA and the size of its ostium. Less often the contrast angiography of the LAA in at least two projections are used for this purpose. Based on these measurements the size of the device is estimated. The positioning of the device in the LAA cavity is ensured by TEE and fluoroscopy. After withdrawal of the sheaths the device is deployed and its proper fixation tested by TEE and manual test and finally the device is released. For the WATCHMAN device the TEE is performed after 45 days to assess proper closure [3,10,12]. Complications of percutaneous LAA closure
Contraindications for percutaneous LAA closure
Atrial fibrillation in patients with valvular heart disease (mitral stenosis)
Other than FA indications for long-term or lifetime anticoagulation (mechanical prosthetic valve, pulmonary embolism and deep vein thrombosis, thrombi in the left atrium or ventricle, incomplete surgical LAA closure)
Low risk: CHADS2 – Vasc Score = 0 (based on PROTECT-AF study)
Use of PLAATO device was assessed in several trials which demonstrated the feasibility and safety of the procedure in long term follow-up. Five year follow-up of 64 patients with permanent or paroxysmal AF revealed reduction of the annualised rate of stroke or TIA in comparison to the one predicted by CHADS2 scoring [14,15]. WATCHMAN is currently the most widely used device for transcatheter LAA closure. After initial reports showing the feasibility, effective sealing of the LAA and its relative safety this technology was evaluated in recently published large randomised, multicentre, prospective trial. The study enrolled 800 patients with non-valvular AF of whom approximately 60% had CHADS2 1 or 2 score and excluded patients with contraindications for oral anticoagulants. PROTECT-AF (WATCHMAN®Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) confirmed non-inferiority to warfarin therapy for prevention of stroke. The procedural success rate was high with effective sealing of the LAA. Only 15% of patients approximately had incomplete sealing of the LAA and required anticoagulation after the procedure. Therefore the use of oral anticoagulants is warranted until the follow-up with TEE after 45 days confirms complete closure. In addition, initially there was an excess (12%) of procedure-related complications including pericardial tamponade and ischemic stroke . Over time the risk of the procedure-related adverse events including device embolisation was reduced as demonstrated by Continued Access Registry which suggest they were related to the learning curve. Recently, improvements in the device design were made and a new generation of WATCHMAN is evaluated in a currently ongoing clinical trial (EVOLVE). So far more than 1,500 patients were treated with WATCHMAN within controlled clinical trials. Amplatzer Cardiac Plug is currently evaluated in multicentre trials and a European registry. Initial experience revealed the 96% procedural success rate and 7% rate of adverse events, including device embolisation (3.5%), tamponade (3.5%) and stroke (2.1%) . Guidelines of the European Society of Cardiology on treatment of AF mention the use of the WATCHMAN device showing non-inferiority to oral anticoagulants in a selected group of patients.
1. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999;82:547-554. 2. Veinot JP, Harrity PJ. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts; implications for echocardiographic examination. Circulation 1997; 96:3112-5. 3. Khattab AA and Meier B. Transcatheter left atrial appendage exclusion, gold or fool's gold? Eur Heart J Suppl (2010) 12 (suppl E): E35-E40.doi: 10.1093/eurheartj/suq008. 4. Shirani J, Alaeddini J. Cardiovasc Pathol. 2000 Mar-Apr;9(2):95-101. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: Implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. 5. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-759. 6. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007;38:624-630]. 7. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070-4. 8. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685 9. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46. 10. Horton RP, Sanchez JE, Wang Y, et al. Percutaneous left atrial appendage occlusion devices. Transseptal catheterization and interventions, ed. Thakur R and Natale A. Cardiotext Publishing LLC. 2010. 11. Jin Hur, Young Jin Kim et al. Left Atrial Appendage Thrombi in Stroke Patients: Detection with Two-Phase Cardiac CT Angiography versus Transesophageal echocardiography. Radiology 2009;251:683 – 680. 12. Hara H, Holmes DR, Van Tassel RA. The left atrial appendage: anatomy, physiology and therapeutic percutaneous closure. Textbook of interventional cardiology, 5th Edition. Topol EJ. Elsevier 2008. 13. Sievert H, Lesh MD, Trepels T. Percutaneous left atrial appendage transcathether occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 1056: 1887-9. 14. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-centre feasibility trials. J Am Coll Cardiol 2005;46:9-14. 15. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009;2:594-600. 16. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for the prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534 – 542.
Grzegorz Smolka and Wojciech Wojakowski Third Division of Cardiology and Acute Coronary Care Unit, Medical University of Silesia, Katowice, Poland